News - Vertex, Research

Filter

Current filters:

VertexResearch

Popular Filters

Vertex outlines progress on cystic fibrosis drug development

17-10-2013

USA-based biotech firm Vertex Pharmaceuticals provided a comprehensive update on recent progress in its…

BiotechnologyKalydecolumacaftorRare diseasesResearchVertexVX-661

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

Vertex shoots up 60% on positive trial results for Kalydeco and VX-661

22-04-2013

US biotech firm Vertex Pharmaceuticals' (Nasdaq: VRTX) shares rocketed 60% to $84.87 Friday morning after…

BiotechnologyKalydecoRare diseasesResearchVertexVX-661

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head

08-04-2013

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis

29-10-2012

Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

Vertex tumbles despite good final data on combo cystic fibrosis therapy

01-07-2012

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

Vertex slumps as firm revises Kalydeco data

30-05-2012

The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Vertex plans for Kalydeco launch

09-01-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) announced its 2012 business objectives in conjunction…

Anti-viralsIncivekKalydecoPharmaceuticalRare diseasesRegulationResearchVertex

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis

06-11-2011

The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top